Although targeted therapies can be an effective strategy for treating cancer, the duration of responses to such therapies, for example, BRAF inhibitors (BRAFi), varies substantially and can be dependent on the origin of the primary tumor.5-11. The gene discussed is BRAF; the disease is cancer.